pulrodemstat (CC-90011) / BMS 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pulrodemstat (CC-90011) / BMS
NCT04350463 / 2019-004194-95: A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Completed
2
92
Europe, US
CC-90011, Nivolumab
Celgene
Neoplasms
12/23
12/23
NCT04628988: A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Completed
1
6
US
CC-90011, Abiraterone, Zytiga, Prednisone, Deltasone
Celgene
Prostatic Neoplasms
05/23
05/23
NCT02875223: A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Terminated
1
75
Europe, Japan
CC-90011, Rifampicin, Itraconazole
Celgene
Lymphoma, Non-Hodgkin, Neoplasms
03/24
03/24
NCT03850067: A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Active, not recruiting
1
90
Europe
CC-90011, Cisplatin, Carboplatin, Etoposide, Nivolumab
Celgene
Small Cell Lung Carcinoma
06/24
06/24

Download Options